Search Results - "Fadden, Riley M."

Early Use of High-Dose Glucocorticoid for the Management of irAE Is Associated with Poorer Survival in Patients with Advanced Melanoma Treated with Anti-PD-1 Monotherapy by Bai, Xue, Hu, Jiani, Betof Warner, Allison, Quach, Henry T, Cann, Christopher G, Zhang, Michael Z, Si, Lu, Tang, Bixia, Cui, Chuanliang, Yang, Xiaoling, Wei, Xiaoting, Pallan, Lalit, Harvey, Catriona, Manos, Michael P, Ouyang, Olivia, Kim, Michelle S, Kasumova, Gyulnara, Cohen, Justine V, Lawrence, Donald P, Freedman, Christine, Fadden, Riley M, Rubin, Krista M, Sharova, Tatyana, Frederick, Dennie T, Flaherty, Keith T, Rahma, Osama E, Long, Georgina V, Menzies, Alexander M, Guo, Jun, Shoushtari, Alexander N, Johnson, Douglas B, Sullivan, Ryan J, Boland, Genevieve M

“…Programmed cell death receptor-1 (PD-1) inhibitors are frontline therapy in advanced melanoma. Severe immune-related adverse effects (irAEs) often require…”
Get full text

Increased risk of cutaneous immune-related adverse events in patients treated with talimogene laherparepvec and immune checkpoint inhibitors: A multi-hospital cohort study by Leung, Bonnie W., Wan, Guihong, Nguyen, Nga, Rashdan, Hannah, Zhang, Shijia, Chen, Wenxin, Cohen, Sonia, Boland, Genevieve M., Sullivan, Ryan J., Fadden, Riley M., Kaufman, Howard L., Kwatra, Shawn G., LeBoeuf, Nicole R., Semenov, Yevgeniy R.

“…Previous studies have shown that combining immune checkpoint inhibitors (ICIs) with talimogene laherparepvec (TVEC) may improve antitumor responses. However,…”
Get full text

Benefit and toxicity of programmed death‐1 blockade vary by ethnicity in patients with advanced melanoma: an international multicentre observational study by Bai, Xue, Shoushtari, Alexander N., Betof Warner, Allison, Si, Lu, Tang, Bixia, Cui, Chuanliang, Yang, Xiaoling, Wei, Xiaoting, Quach, Henry T., Cann, Christopher G., Zhang, Michael Z., Pallan, Lalit, Harvey, Catriona, Kim, Michelle S., Kasumova, Gyulnara, Sharova, Tatyana, Cohen, Justine V., Lawrence, Donald P., Freedman, Christine, Fadden, Riley M., Rubin, Krista M., Frederick, Dennie T., Flaherty, Keith T., Long, Georgina V., Menzies, Alexander M., Sullivan, Ryan J., Boland, Genevieve M., Johnson, Douglas B., Guo, Jun

“…Background Programmed cell death receptor‐1 (PD‐1) monotherapy is a standard treatment for advanced cutaneous melanoma, but its efficacy and toxicity are…”
Get full text

Clinical features of acute kidney injury in patients receiving dabrafenib and trametinib by Seethapathy, Harish, Lee, Meghan D, Strohbehn, Ian A, Efe, Orhan, Rusibamayila, Nifasha, Chute, Donald F, Colvin, Robert B, Rosales, Ivy A, Fadden, Riley M, Reynolds, Kerry L, Sullivan, Ryan J, Kaufman, Howard L, Jhaveri, Kenar D, Sise, Meghan E

“…Abstract Background Our objective was to characterize the incidence, risk factors and clinical features of acute kidney injury (AKI) in patients receiving…”
Get full text

Acute Kidney Injury Following Encorafenib and Binimetinib for Metastatic Melanoma by Seethapathy, Harish, Bates, Halla, Chute, Donald F., Strohbehn, Ian, Strohbehn, Samuel, Fadden, Riley M., Reynolds, Kerry L., Cohen, Justine V., Sullivan, Ryan J., Sise, Meghan E.

Get full text